Navigation Links
Nile Therapeutics Reports 2011 Third Quarter Financial Results

SAN MATEO, Calif., Nov. 14, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011.

Financial ResultsFor third quarter of 2011, Nile reported research and development collaboration income relating to its cenderitide program of approximately $0.8 million, as compared to none in the third quarter of 2010. The net loss for the third quarter of 2011 was approximately $1.1 million, or $0.03 per share, compared to a net loss of approximately $1.8 million, or $0.05 per share, during the third quarter of 2010. Weighted-average shares outstanding for the third quarter of 2011 were 39.7 million.

Net cash used in operating activities in the third quarter of 2011 was approximately $0.7 million. As of September 30, 2011, Nile had cash and cash equivalents of approximately $2.6 million compared to approximately $3.4 million as of December 31, 2010.

Update on CenderitideIn October 2011, Nile completed patient dosing of an open-label Phase I clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. The trial was an important step towards developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period.

The Phase I clinical trial was designed to evaluate the required dosage to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous subcutaneous infusion of either of two fixed doses of cenderitide or placebo. In Part C, 12 patients received a 24-hour continuous subcutaneous infusion of either a weight-based dose of cenderitide, or placebo. All infusions were delivered through Medtronic, Inc.'s subcutaneous pump technology. Nile plans to announce top-line data from the clinical trial in November 2011, and intends to present the complete data at an upcoming scientific conference.

About Heart FailureHeart failure is the fastest-growing clinical cardiac disease in the U.S. according to the American Heart Association, affecting over 5 million Americans. Over 1 million patients in the U.S. each year are hospitalized with ADHF, an acute exacerbation of heart failure. ADHF is the is the most frequent cause of hospital admission in the U.S. for patients older than 65 years, generating annual inpatient costs of more than $35 billion. Within 90 days following admission for ADHF, approximately 40% of patients return to the hospital. Nile believes that a decrease in the ADHF re-hospitalization rate, which is the clinical target of the cenderitide development program, could both improve the quality of life for patients and decrease the annual inpatient cost of heart failure.

About Nile TherapeuticsNile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. The cenderitide program was granted Fast Track status by the United States Food and Drug Administration. More information on Nile can be found at Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, Nile's plans for further development of cenderitide, Nile's ability to obtain FDA approval of cenderitide in the post-acute setting and Nile's beliefs about the potential impact of a decrease of the ADHF re-hospitalization rate on the quality of life for patients, are forward-looking statements. Forward-looking statements also include statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of cenderitide, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to obtain additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, the final results of the Phase I trial of cenderitide may not support Nile's preliminary findings, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 14, 2011. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.NILE THERAPEUTICS, INC.



(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2011201020112010IncomeCollaboration income$
-Operating expenses:Research and development1,470,0911,148,6412,795,3543,517,822General and administrative499,273664,0951,597,8551,732,745Total operating expenses1,969,3641,812,7364,393,2095,250,567Loss from operations(1,156,364)(1,812,736)(3,234,209)(5,250,567)Other income (expense):Interest income1,8805,9544,91217,526Interest expense----Other income (expense)10,411(2,711)8,901(2,793)Total other income (expense)

12,2913,24313,81314,733Net loss$
(5,235,834)Basic and diluted loss per share$
(0.17)Weighted-average common shares outstanding

39,707,76434,563,07336,526,34631,338,963NILE THERAPEUTICS, INC.


CONDENSED BALANCE SHEETSSeptember 30, 2011December 31, 2010(unaudited)ASSETS Current assets Cash and cash equivalents

3,378,155Prepaid expenses and other current assets

420,653219,095Total current assets

3,027,9893,597,250 Property and equipment, net  

10,88616,765 Other noncurrent assets

51,93851,938Total assets

3,665,953 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts  payable

332,380Accrued  expenses and other current liabilities

177,317652,275Due to related party

36,16784,430Total current liabilities

717,8171,069,085Total stockholders' equity

2,372,9962,596,868Total liabilities and stockholders' equity


SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Orexigen® Therapeutics Reports Third Quarter Financial Results
3. Silence Therapeutics Provides Corporate and Development Update
4. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
5. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
6. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
7. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Post Your Comments:
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... -- Symic, a clinical-stage biotherapeutics company developing multiple compounds that ... that it has secured $25 million in a Series ... lead candidates SB-030 and SB-061. The financing was led ... existing major investors, as well as several new investors. ... Symic to over $43 million since being founded in ...
(Date:12/1/2015)... 1, 2015 ... "2016 U.K. Virology and Bacteriology Testing Market: ... Tests, Supplier Shares by Test, Innovative Technologies, ... offering.  --> ) has ... Virology and Bacteriology Testing Market: Sales and ...
(Date:11/30/2015)... radiology technique shows promise for helping morbidly obese patients lose ... presented today at the annual meeting of the Radiological Society ... --> --> Gastric artery embolization ... way to stop bleeding in emergency situations, but the idea ... is new. Mubin Syed , M.D., interventional radiologist ...
Breaking Biology Technology:
(Date:11/17/2015)... 2015 Paris from 17 ... Paris from 17 th until 19 ... innovation leader, has invented the first combined scanner in the ... same scanning surface. Until now two different scanners were required: one ... capture both on the same surface. This innovation is ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
Breaking Biology News(10 mins):